External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

External broker reports(aggregated public sources)

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<div><div><div><div><ul><li>PYC provided an update to its existing VP-001 Phase I/II dataset in RP11 (Retinitis Pigmentosa 11), a rare blinding eye disease, to be presented this weekend at AVPRS (Congress of the Asia-Pacific Vitreo-Retina Society).</li><li>Data were broadly positive, noting the full dataset is still incomplete, especially out at the six-month timepoint.</li><li>Net-net, we view the consistency in benefit across LLVA (low luminance visual acuity), and reduced number of scotomas (blind spots) as a positive sign that VP-001 is having a positive impact on functional outcomes. </li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC provided an update to its existing VP-001 Phase I/II dataset in RP11 (Retinitis Pigmentosa 11), a rare blinding eye disease, to be presented this weekend at AVPRS (Congress of the Asia-Pacific Vitreo-Retina Society).Data were broadly positive, noting the full dataset is still incomplete, especially out at the six-month timepoint.Net-net, we view the consistency in benefit across LLVA (low luminance visual acuity), and reduced number of scotomas (blind spots) as a positive sign that VP-001 is having a positive impact on functional outcomes. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - Net Positive VP-001 Update at APVRS

<ul><li>This morning, PYC released preclinical data in two species (mice, non-human primate) for its PYC-003 program in ADPKD (autosomal dominant polycystic kidney disease).</li><li>While we generally do not attribute material value to animal data, we note this set<br>of data is extremely important from a validation perspective - if there were any issues around safety, PK/PD and delivery to cyst producing cells, this would have raised concerns around the potential future of the drug candidate.</li><li>Fortunately, this is not the case - the data implies that VP-003 is responsible for disease reversal, including anatomical restoration and regained kidney function. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

This morning, PYC released preclinical data in two species (mice, non-human primate) for its PYC-003 program in ADPKD (autosomal dominant polycystic kidney disease).While we generally do not attribute material value to animal data, we note this set of data is extremely important from a validation perspective - if there were any issues around safety, PK/PD and delivery to cyst producing cells, this would have raised concerns around the potential future of the drug candidate.Fortunately, this is not the case - the data implies that VP-003 is responsible for disease reversal, including anatomical restoration and regained kidney function. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC-003 Shows Positive Preclinical Safety and Efficacy Data in Mice and NHPs

<div><ul><li>This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.</li><li>While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.</li><li>Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.</li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - The RNA Space Is Heating Up

<ul><li>PYC reported its FY24 result, in line with the quarterly released in July. R&amp;D spend for the year was in line at $56m noting the company is punching well above its weight<br>in terms of capital efficiency.</li><li>Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with competitor programs.</li><li>Recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC reported its FY24 result, in line with the quarterly released in July. R&amp;D spend for the year was in line at $56m noting the company is punching well above its weight in terms of capital efficiency.Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with competitor programs.Recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - FY24: Clear Line of Sight to Multiple Near-Term Potential Catalysts

<div><ul><li>PYC Therapeutics recently presented at the Canaccord Genuity Growth Conference<br>in Boston, MA, as well as direct peers Regulus Therapeutics (RGLS-NASDAQ: US<br>$1.59 | BUY, TP US$28.00 | Whitney Ijem, Canaccord Genuity LLC), which also has an ADPKD asset, and broader industry feedback within the ophthalmology segment (Kiora Pharmaceuticals - KPRX-NASDAQ).</li><li>Retinitis Pigmentosa 11 (RP11) updates provide early proof of concept, with more potential catalysts to come.</li><li><div><div><div><div><p>VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the treated eyes of two patients.</p></div></div></div></div></li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC Therapeutics recently presented at the Canaccord Genuity Growth Conference in Boston, MA, as well as direct peers Regulus Therapeutics (RGLS-NASDAQ: US $1.59 | BUY, TP US$28.00 | Whitney Ijem, Canaccord Genuity LLC), which also has an ADPKD asset, and broader industry feedback within the ophthalmology segment (Kiora Pharmaceuticals - KPRX-NASDAQ).Retinitis Pigmentosa 11 (RP11) updates provide early proof of concept, with more potential catalysts to come.VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the treated eyes of two patients.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Australia

Pyc Therapeutics Limited operates as a pharmaceutical company. The Company develops drugs and medicine for various types of diseases. Pyc Therapeutics serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PYC Therapeutics (PYC AU)

PYC Therapeutics Limited - Net Positive VP-001 Update at APVRS

Given our confidence on the safety profile of VP-001 we maintain our price target of $2.40 (VP-001 $0.90, ADPKD $0.90, ADOA $0.40 and PMS $0.20).

Canaccord Genuity

PYC-003 Shows Positive Preclinical Safety and Efficacy Data in Mice and NHPs

This morning, PYC released preclinical data in two species (mice, non-human primate) for its PYC-003 program in ADPKD (autosomal dominant...

Canaccord Genuity

PYC Therapeutics Limited - The RNA Space Is Heating Up

While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general

Canaccord Genuity

PYC Therapeutics Limited - FY24: Clear Line of Sight to Multiple Near-Term Potential Catalysts

Recall PYC is a platform clinical stage gene therapy company, with proprietary technology aimed at addressing shortcomings associated with...

Canaccord Genuity

PYC Therapeutics Limited - Flash Update

VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the...

Canaccord Genuity

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)